Show simple item record

dc.contributor.authorZahedi, S
dc.contributor.authorShamsasenjan, K
dc.contributor.authorMovassaghpour, A
dc.contributor.authorAkbarzadehlaleh, P
dc.date.accessioned2018-08-26T09:31:20Z
dc.date.available2018-08-26T09:31:20Z
dc.date.issued2016
dc.identifier10.15171/apb.2016.054
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57011
dc.description.abstractPurpose: Mesenchymal Stem Cells (MSCs) are one of the essential members of Bone Marrow (BM) microenvironment and the cells affect normal and malignant cells in BM milieu. One of the most important hematological malignancies is Multiple Myeloma (MM). Numerous studies reported various effects of MSCs on myeloma cells. MSCs initiate various signaling pathways in myeloma cells, particularly NF-k?. NF-k? signaling pathway plays pivotal role in the survival, proliferation and resistance of myeloma cells to the anticancer drugs, therefore this pathway can be said to be a vital target for cancer therapy. This study examined the relationship between U266 cells and MSCs. Methods: U266 cells were cultured with Umbilical Cord Blood derived-MSCs (UCBMSCs) and Conditioned Medium (C.M). Effect of UCB-MSCs and C.M on proliferation rate and CD54 expression of U266 cells were examined with MTT assay and Flowcytometry respectively. Furthermore, expression of CXCL1, PECAM-1, JUNB, CCL2, CD44, CCL4, IL-6, and IL-8 were analyzed by Real Time-PCR (RT-PCR). Moreover, status of p65 protein in NF-k? pathway assessed by western blotting. Results: Our findings confirm that UCB-MSCs support U266 cells proliferation and they increase CD54 expression. In addition, we demonstrate that UCB-MSCs alter the expression of CCL4, IL-6, IL-8, CXCL1 and the levels of phosphorylated p65 in U266 cells. Conclusion: Our study provides a novel sight to the role of MSCs in the activation of NFk? signaling pathway. So, NF-k? signaling pathway will be targeted in future therapies against MM. © 2016 The Authors.
dc.language.isoEnglish
dc.relation.ispartofAdvanced Pharmaceutical Bulletin
dc.subjectCD31 antigen
dc.subjectCXCL1 chemokine
dc.subjectHermes antigen
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectinterleukin 6
dc.subjectinterleukin 8
dc.subjectmacrophage inflammatory protein 1beta
dc.subjectmonocyte chemotactic protein 1
dc.subjecttranscription factor JunB
dc.subjecttranscription factor RelA
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer resistance
dc.subjectcell interaction
dc.subjectcell proliferation
dc.subjectcell survival
dc.subjectcell viability
dc.subjectcentrifugation
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectenzyme activation
dc.subjectflow cytometry
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmesenchymal stem cell
dc.subjectMTT assay
dc.subjectoptical density
dc.subjectprotein expression
dc.subjectprotein phosphorylation
dc.subjectradioimmunoprecipitation
dc.subjectreal time polymerase chain reaction
dc.subjectsignal transduction
dc.subjectU266 cell line
dc.subjectumbilical cord blood
dc.subjectupregulation
dc.subjectWestern blotting
dc.titleNF-K? activation in U266 cells on mesenchymal stem cells
dc.typeReview
dc.citation.volume6
dc.citation.issue3
dc.citation.spage415
dc.citation.epage422
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.15171/apb.2016.054


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record